AbbVie's Humira manufacturing plant in Puerto Rico. Photo: AbbVie

Price hikes on 7 prominent drugs — all of them above the rate of medical inflation, none supported by clinical evidence — cost Americans more than $5 billion over the last two years, according to a new report from the Institute for Clinical and Economic Review.

Why it matters: Drugmakers weren't hiking prices because their medications were safer or more effective than when they were approved. They did it because they could.

By the numbers: Here are the drugs (and manufacturers) highlighted in ICER's report, along with the increase in net spending attributable to each drug's price increase.

  • Humira (AbbVie): $1.9 billion
  • Rituxan (Roche): $806 million
  • Lyrica (Pfizer): $688 million
  • Truvada (Gilead Sciences): $550 million
  • Neulasta (Amgen): $489 million
  • Cialis (Eli Lilly): $403 million
  • Tecfidera (Biogen): $313 million

Those figures aren't just the dollars Americans spent on drug copays and other out-of-pocket costs. They mostly reflect the higher amounts people paid through health insurance premiums and taxes.

A common thread: Most of those drugs have faced competition from generics or biosimilars. Erin Fox, a pharmacotherapy professor at the University of Utah, said in a tweet that is "a typical time to jack up prices without adding value."

The other side: ICER published an appendix in the report, which has been in the works for months, that included rebuttals from the pharmaceutical firms in question.

  • The companies criticized the analysis for not factoring in the "value" of their drugs and lives saved, but ICER responded that "new evidence must provide information different from what was previously believed in order to support a price increase."

Go deeper

20 Republican former U.S. attorneys endorse Biden, call Trump "a threat to the rule of law"

Photo: Mandel Ngan/AFP via Getty Images

Twenty Republican former U.S. Attorneys on Tuesday endorsed Joe Biden while saying that "President Trump's leadership is a threat to rule of law" in the U.S., the Washington Post reports.

What they're saying: In the letter, the former prosecutors criticize Trump's use of the Department of Justice, saying the president expects the DOJ to "to serve his personal and political interests."

  • "He has politicized the Justice Department, dictating its priorities along political lines and breaking down the barrier that prior administrations had maintained between political and prosecutorial decision-making," the letter says.
Updated 37 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Politics: Axios-Ipsos poll: Federal response has only gotten worse — The swing states where the pandemic is raging.
  2. Health: The coronavirus is starting to crush some hospitals — 13 states set single-day case records last week.
  3. Business: Winter coronavirus threat spurs new surge of startup activity.
  4. Media: Pandemic causes cable and satellite TV providers to lose the most subscribers ever.
  5. States: Nearly two dozen Minnesota COVID cases traced to 3 Trump campaign events.
  6. World: Unrest in Italy as restrictions grow across Europe.

Ted Cruz defends GOP's expected return to prioritizing national debt

Sen. Ted Cruz (R-Texas) told "Axios on HBO" on Monday that he wishes reining in the national debt was a higher priority for President Trump.

Why it matters: Trump pledged during the 2016 campaign to reduce the national debt and eliminate it entirely within eight years, though he also deemed himself "the king of debt" and said there were some priorities that required spending. In the fiscal year that ended in September, the deficit reached a record $3.1 trillion.